Acquisitions, Licensing and Other Arrangements - ObsEva (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Nov. 21, 2022 |
Dec. 31, 2023 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Asset acquisition | ||||
| Impairment of intangible asset | $ 14,253 | |||
| Revenue recognized | $ 6,650 | 2,650 | ||
| Obseva - Ebopiprant IP | ||||
| Asset acquisition | ||||
| Impairment of intangible asset | 14,253 | |||
| License Agreement | ObsEva, Organon | ||||
| Asset acquisition | ||||
| Revenue recognized | $ 0 | 0 | ||
| License Agreement | ObsEva, Organon | Obseva - Ebopiprant IP | ||||
| Asset acquisition | ||||
| Impairment of intangible asset | $ 14,200 | $ 14,200 | ||
| ObsEva IP | ||||
| Asset acquisition | ||||
| Closing cash payment | $ 15,000 | |||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|